Last reviewed · How we verify
NCT05788510: TNF-VAX
Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy
trial testing Pneumococcal vaccine in Pneumococcal Vaccine in 106 participants. Completed in 6 May 2023.
6 May 2023
Quick facts
| Lead sponsor | Hôpital NOVO |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 106 |
| Start date | 3 April 2023 |
| Primary completion | 6 May 2023 |
| Estimated completion | 6 May 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Pneumococcal vaccine
Conditions studied
- Pneumococcal Vaccine — all drugs for Pneumococcal Vaccine →
Sponsor
Hôpital NOVO — full company profile →
Who can join
18 and older, any sex, with Pneumococcal Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital. The aim of this study is to assess the status of pneumococcal vaccination in patients at the NOVO hospital - Pontoise site, who have received anti-TNF alpha therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05788510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pneumococcal vaccine
Trials testing the same drug.
- NCT06213506 — A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal S · Phase 2 · recruiting
- NCT04515147 — A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults · Phase 2 · completed
Other recruiting trials for Pneumococcal Vaccine
Currently open trials in the same condition.
- NCT06181656 — Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemor · recruiting
Other Hôpital NOVO trials
Trials by the same sponsor.
- NCT07394478 — Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica · not yet recruiting
- NCT07412340 — Disarticulation Septoplasty Versus Classical Way · not yet recruiting
- NCT07298070 — Functional and Aesthetic Outcomes Following Lower Lip Reconstruction · not yet recruiting
- NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
- NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05788510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital NOVO
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05788510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing